-
PR
Rege Nephro Co., Ltd. Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals, Inc.
-
PR
Rege Nephro Co., Ltd. and Roche Enter into Collaborative Research Agreement on iPSC-Derived Human Disease Models
-
PR
Professor Kenji Osafune, Chief Scientific Advisor, ran the Osaka Marathon 2025
-
PR
Patient Enrollment for Phase II clinical trial for Tamibarotene for ADPKD has been completed
-
PR
Professor Osafune, Chief Scientific Advisor, to deliver a Lecture at THE 9TH ACADEMIC GOVERNMENT SYMPOSIUM ON REGENERATIVE MEDICINE
-
Rege Nephro Co., Ltd. Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals, Inc.
-
Rege Nephro Co., Ltd. and Roche Enter into Collaborative Research Agreement on iPSC-Derived Human Disease Models
-
Professor Kenji Osafune, Chief Scientific Advisor, ran the Osaka Marathon 2025
-
Patient Enrollment for Phase II clinical trial for Tamibarotene for ADPKD has been completed
-
Professor Osafune, Chief Scientific Advisor, to deliver a Lecture at THE 9TH ACADEMIC GOVERNMENT SYMPOSIUM ON REGENERATIVE MEDICINE
-
Upcoming Feature on NHK World JAPAN Science View: Freeing Patients from Dialysis! -Dr. Kenji OSAFUNE’s Challenge
-
Our business was introduced in Science Japan, an online magazine published by JST.
-
An article about Toshihiro Ishikiriyama, our president, was published in AnswersNews, serial column: Venture Round Visit Report.
-
Featured in Nikkei newspaper, its electronic version, Asahi Shimbun DIGITAL and many other media.
-
Published in the Nikkei newspaper and the electronic version.